Request Legal Help Now - Free
LAWSUITS NEWS & LEGAL INFORMATION

SGLT2 Inhibitor Forxiga Safety Review Launched Legal News Articles & Interviews

FDA Mandates New Study and Warnings on Labels for SGLT2 Inhibitors

FDA Mandates New Study and Warnings on Labels for SGLT2 Inhibitors December 7, 2015. By Lucy Campbell.
Washington, DC: A review by the US Food and Drug Administration (FDA) of specific class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors, has resulted in the agency adding warnings to the labels concerning the risks for serious urinary tract infections (UTIs) too much acid in the blood. Both these conditions can result in hospitalization.
Read [ FDA Mandates New Study and Warnings on Labels for SGLT2 Inhibitors ]

Safety Review of SGLT2 Inhibitors Initiated by Health Canada

Safety Review of SGLT2 Inhibitors Initiated by Health Canada June 22, 2015. By Lucy Campbell.
Ottawa, Canada Health Canada has initiated a safety review for the prescription diabetes drugs Dapagliflozin (Forxiga) and canagliflozin (Invokana), and the risk of ketoacidosis, a serious condition that leads to high levels of blood acids called ketones. These drugs are approved in Canada for use in patients with type 2 diabetes to improve blood sugar levels, along with diet and exercise.
Read [ Safety Review of SGLT2 Inhibitors Initiated by Health Canada ]

Request Legal Help Now! - Free